Nothing Special   »   [go: up one dir, main page]

Iatrakis et al., 2006 - Google Patents

Polycystic ovarian syndrome, insulin resistance and thickness of the endometrium

Iatrakis et al., 2006

View PDF
Document ID
6560697559047799439
Author
Iatrakis G
Tsionis C
Adonakis G
Stoikidou M
Anthouli-Anagnostopoulou F
Parava M
Vouxinou A
Georgopoulos N
Kourounis G
Publication year
Publication venue
European Journal of Obstetrics & Gynecology and Reproductive Biology

External Links

Snippet

INTRODUCTION: Disorders possibly associated with insulin resistance (IR) are hyperandrogenemia, hirsutism, irregular menstrual cycles, central obesity and polycystic ovarian syndrome (PCOS). It is known that PCOS is related to a high risk of endometrial …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone

Similar Documents

Publication Publication Date Title
Iatrakis et al. Polycystic ovarian syndrome, insulin resistance and thickness of the endometrium
Witchel et al. The diagnosis and treatment of PCOS in adolescents: an update
Kumar et al. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS)
Cook et al. Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women
Chang et al. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups
Ersöz et al. Causes of gynaecomastia in young adult males and factors associated with idiopathic gynaecomastia
Hofmann et al. Inhibin-B: the physiologic basis of the clomiphene citrate challenge test for ovarian reserve screening
Carmina et al. Do hyperandrogenic women with normal menses have polycystic ovary syndrome?
Bath et al. Hypothalamic–pituitary–ovarian dysfunction after prepubertal chemotherapy and cranial irradiation for acute leukaemia
Farquhar et al. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding
Katsikis et al. Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome
Chang A practical approach to the diagnosis of polycystic ovary syndrome
Abbott et al. Clustering of PCOS-like traits in naturally hyperandrogenic female rhesus monkeys
Wood et al. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys
Amer et al. The influence of circulating anti-Müllerian hormone on ovarian responsiveness to ovulation induction with gonadotrophins in women with polycystic ovarian syndrome: a pilot study
El‐Khayat et al. Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy
Sun et al. Healthy post-menarchal adolescent girls demonstrate multi-level reproductive axis immaturity
Velija-Ašimi Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment
Romualdi et al. The role of anti-Müllerian hormone in the characterization of the different polycystic ovary syndrome phenotypes
Amato et al. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome
Nouri et al. Association between BMI and gene expression of anti‐Müllerian hormone and androgen receptor in human granulosa cells in women with and without polycystic ovary syndrome
Hviid Saxtorph et al. Are different markers of endometrial receptivity telling us different things about endometrial function?
Roth et al. Luteal phase dynamics of follicle‐stimulating and luteinizing hormones in obese and normal weight women
Kohzadi et al. Relationship between serum levels of anti-mullerian hormone, adiponectin and oxidative stress markers in patients with polycystic ovary syndrome
Buyalos et al. The relationship between circulating andorgens, obesity, and hyperinsulinemia on serum insulin-like growth factor binding protein-1 in the polycystic ovarian syndrome